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Congenital medulloblastoma is a rare brain tumor that appears in less than 1% of pediatric patients. Congenital 
medulloblastoma has a poor prognosis and should be suspected in patients with clinical manifestations of hyporeactivity, 
slow suction reflexes, and the presence of hydrocephalus. Herein we present the case of a 12-day-old female newborn 
who developed non-communicative hydrocephalus, hyporeactivity, and hyporeflexia. Magnetic resonance imaging of her 
brain showed a heterogeneous and cystic mass on the posterior cranial fossa. A suboccipital craniotomy was performed. 
The histopathologic analysis reported a congenital medulloblastoma. She remained in hospital until her death at 112 
days old. This is one of the first case reports with clinical-radiological and pathological documentation. Awareness of 
this diagnosis can allow prenatal intervention, rendering a better prognosis. This case report exemplifies the importance 
of good prenatal follow-up. 
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INTRODUCTION
A congenital medulloblastoma is extremely rare 
compared with medulloblastomas in general. It is 
usually diagnosed postnatally, is a form of neoplasm 
that originates in the posterior fossa at the level of 
the cerebellum, and is a highly aggressive neoplasm 
characterized by undifferentiated cells.1
In general, congenital brain tumors—one of the 
rarest of all tumors reported in the literature (which 
includes medulloblastoma)—are usually diagnosed 
within the first 2 months of life.2,3 The incidence has 
increased over the past 20 years and accounts for 
0.5-1.5% of all pediatric brain tumors; however, 
the level of incidence differs depending on the 
patient’s country of residence. These tumors are 
different in histology from those reported in the first 
or second year of life; teratoma appears to be the 
most common, followed by astrocytomas or primitive 
neuroectodermal tumors as reported by Wakai et al.,4 
Sugimoto et al.,5 and Alamo et al.6 Even in this large 
case series, medulloblastoma tumors are rare. The 
clinical presentation is insidious, and the condition 
tends to have a high mortality rate; however, in the 
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future, the prognosis is expected to improve because of 
prenatal diagnosis due to ultrasonography and magnetic 
resonance imaging (MRI).
This report presents one of the very first cases 
to use pathological images and imaging studies. 
The importance of this case report is that congenital 
medulloblastoma shows a strange pathology, which 
usually has a high mortality rate; it also can have a 
similar clinical presentation to other congenital brain 
tumors and shows a very similar pattern on imaging.
CASE REPORT
A female baby was born by uneventful vaginal 
delivery at 36.5 weeks’ gestation with an APGAR score 
of 8 and 9 at the first and fifth minutes, respectively. 
Her weight was 2.3 kg, her length was 48 cm, and 
her cephalic perimeter was 28 cm. The mother was 
39 years old (gravida 6: three cesarean sections, two 
vaginal deliveries, one abortion) who attended prenatal 
consultation during the first trimester of pregnancy. 
On the baby’s first day, she had ocular secretion, 
jaundice, hyporeactivity, and slow suction reflexes. On 
day 3, she presented six apnea episodes. A transcranial 
ultrasound reported obstructive hydrocephalus. The 
MRI (Figure 1A) showed a heterogeneous and cystic 
mass on the posterior cranial fossa, which compressed 
ventricles III and IV, causing severe dilatation of the 
ventricular system.
The patient was submitted to a suboccipital 
craniotomy, and the intraoperative pathological 
assessment depicted a primitive and undifferentiated 
neoplasm with neuroectodermal features. The final 
pathology diagnosis was medulloblastoma (WHO 
Grade IV; synaptophysin+, CD56+, beta-catenin+, and 
INI1+) (Figure 2).
The patient was submitted to an exchange 
blood transfusion on day 6, which resulted in clinical 
improvement. The neurosurgery team proceeded with 
a suboccipital craniotomy on day 21, resecting 40% 
of the total mass, which, on day 24, was complicated 
by a serous-draining fistula. One week later (day 31), 
the patient presented respiratory distress and oxygen 
desaturation due to Klebsiella pneumoniae pneumonia 
and required orotracheal intubation and an antibiotic 
regimen with vancomycin and levofloxacin. On day 
33, she presented clinical improvement; however, 1 
week later (day 40), the intracranial pressure increased 
again. Hyperchloremic metabolic acidosis ensued, 
and the fistula continued to drain serous-sanguineous 
fluid. The patient started with partial and focal seizures 
that manifested in the upper right limb and included 
sucking movements. Computed tomography of her 
brain was performed and revealed active bleeding 
and increased mass volume with medulla oblongata 
Figure 1. A – Magnetic resonance imaging, sagittal section: T2 sequence shows a heterogeneous cystic mass causing 
important dilatation of the ventricle system; B – Computed tomography of the coronal section, parenchymal (brain) 
window: shows a heterogeneous cystic mass causing important dilatation of the ventricle system.
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involvement (Figure 1B). Her clinical status worsened 
with desaturation, edema, hypothermia, and ultimately 
with mydriatic and areflexic pupils. Cardiopulmonary 
arrest and death were declared on day 112.
DISCUSSION
Medulloblastoma, an embryonal neuroepithelial 
tumor of the cerebellum, is known to be the most 
common malignant brain tumor in Pediatrics (WHO 
Grade IV), representing 20% of all brain tumors in this 
age group. The outcome is poor, and a fatality occurs in 
one-third of all the patients with this condition despite 
the therapeutic improvements.7
The associat ion of maternal diet and the 
higher risk of medulloblastoma was raised but not 
confirmed.8,9 However, viral infections and familial 
history of central nervous system tumors seem to be 
risk factors.10-12
Children are 10 times more likely to be affected 
by medulloblastoma than adults, and its incidence 
is calculated to be 1.5 per million population in the 
USA.14 Even so, congenital cerebellar medulloblastoma 
is extremely rare. The clinical presentation comprises 
respiratory distress, vomiting, hypoactivity, and high 
mortality.13-17
Symmetric ventriculomegaly and a midline cerebellar 
lesion (isointense with obstructive hydrocephalus) have 
Figure 2. Photomicrographs of the brain tumor. A – Large sheets of small, round cells can be observed in the complete 
absence of any other components (H&E, 10X); B – High nuclear/cytoplasmic ratio, nuclear molding, and variability 
in the shape of nuclei are evident in this hypercellular neoplasm rendering a primitive, embryonal appearance (H&E, 
40X); C – Retained INI1 (40X); D – Focal and partial reactivity for CD 56 in the neoplastic cells (40X); E – Beta-catenin 
membrane stain was positive (40X). c-MYC was negative. Additional stains for synaptophysin (focally positive), 
CD99 (negative), and KI67 (positive, 70%) were performed.
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been previously described and can be compared with 
our patient.1,18
Congenital anomalies and genetic syndromes have 
been described as being related to medulloblastoma; 
however, in a series of 173 patients with medulloblastoma, 
as reported by Evans et al.,19 no congenital medulloblastoma 
was reported.
In Hispanic literature, we found a few cases with 
similar clinical presentation to our case.20,21 The largest 
case series comprised just two cases of congenital 
medulloblastoma, where one patient was 5 months 
old.22 In a Spanish case series—in a Madrid hospital—
where 9 neonatal tumors were reported from 1983 to 
2001, only 1 was a congenital medulloblastoma.23 This 
is clearly because neonatal brain tumors, in general, 
are less than 1%.24 From 1948 to 1993 there were only 
24 cases of congenital medulloblastoma, and all the 
patients except one died in the first 6 weeks.25
Other relevant diagnoses to take into account are 
teratoid/rhabdoid immature tumors (ATRT), a highly 
aggressive neoplasm that affects very young children, 
arises in the cerebellum and is composed of rhabdoid 
and other mesenchymal cells, and the loss of both 
copies of the INI1gene is it molecular signature; and 
embryological brain (PNETs), these tumors produce 
symptoms within the first 2 months of life (posterior 
fossa location) causing hydrocephalus, vomiting, and 
immunochemistry should be done to facilitate the 
tumor identification using the 2016 WHO classification 
of brain tumors.26,27 These immunochemistry stains 
included INI-1, synaptophysin, beta-catenin, among 
others, the molecular analysis also should be performed, 
genome-wide SNP microarray, and PCR should be done 
in autopsy and surgical CNS tumor specimen from 
all the infants under 6 months of age to determine 
the molecular characteristics that differ from tumors 
of older children, Viaene et al.28 recognizes the need 
to grouping medulloblastomas and atypical teratoid 
rhabdoid tumors separately from other embryonal 
tumors because the unique molecular profiles, in 
congenital tumors it is remarkable the presence of 
desmoplastic/nodular histological variant, but the 
classical histologic variant could also be seen, the 
most common location is the posterior fossa and the 
SHH activated TP53-wildtype is the most common 
molecular subgroup in congenital medulloblastoma 
(also is described to be the most common in infants), in 
classic medulloblastoma the most common molecular 
pathway is the one following MYCN amplification 
with isochromosome 17q and is presented in adults 
and older children as the one pathway following 
WNT-activated were beta-catenin is mutated and is 
related to Turcot Syndrome, classic medulloblastoma 
is considered a highly cellular tumor composed of 
diffuse masses of small, undifferentiated oval or 
round cells (as the one reported in our institution), 
the desmoplastic/nodular histological variant is 
permeated by fine collagen (reticulin) fibers with pale 
islands (center of the nodules that are reticulin-free) 
this histologic type is most common in infants and is 
considered to have a better prognosis (there is a direct 
relation between SHH-activated pathway and D/N 
histology and is related with Gorlin Syndrome)), it is 
important to remark that when appears, congenital 
medulloblastoma is within the first two months of 
life or prenatally, and some of them in the setting 
of a tumor predisposition syndrome such as Gorlin 
Syndrome, the study of Viaene et al.28 is one of the first 
in their type given principal importance to histologic 
and molecular characteristics of congenital tumors of 
CNS and illustrate the need of more studies of this 
specific characteristics to improve the future treatment 
and diagnosis and understanding.29-31
CONCLUSION
Congenital medulloblastoma is one of the 
most uncommon malignant brain tumors that can 
be diagnosed before birth. In general, its clinical 
presentation, imaging, and the outcome are very 
similar. When this condition is suspected, an MRI 
should be performed before birth, which may permit 
intrauterine intervention, and thus render a better 
prognosis Molecular and genetic research should be 
done in central nervous system tumors typification to 
understand their unique characteristics and treatment.
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